Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
Relatlimab is a type of human immunoglobulin G4 monoclonal blocking antibody. It is the world’s first Lymphocyte-Activation Gene-3 (LAG-3) inhibitor and the third immune checkpoint inhibitor with clinical application, following PD-1 and CTLA-4. Relatlimab can bind to the LAG-3 receptor which blocks...
| Հիմնական հեղինակներ: | , , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
Frontiers Media S.A.
2024-01-01
|
| Շարք: | Frontiers in Pharmacology |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1349081/full |